Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $58 from $45 and keeps an Overweight rating on the shares. The firm notes Capricor ended 2025 with cash of $318M to fund operations through 2027. The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for deramiocel and set a PDUFA date of August 22nd. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.